Alpha-1-Proteinase Inhibitor
Brand name: Prolastin C
Rank #122 of 500 drugs by total cost
$137.9M
Total Cost
12,352
Total Claims
$137.9M
Total Cost
713
Prescribers
$11K
Cost per Claim
39
Beneficiaries
12,364
30-Day Fills
$193K
Avg Cost/Provider
17
Avg Claims/Provider
About Alpha-1-Proteinase Inhibitor
Alpha-1-Proteinase Inhibitor (sold as Prolastin C) was prescribed 12,352 times by 713 Medicare Part D providers in 2023, costing the program $137.9M. At $11K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 119 | Ofatumumab (Kesimpta Pen) | $144.6M | 14,774 |
| 120 | Emtricitab/Rilpiviri/Tenof Ala (Odefsey) | $144.1M | 37,441 |
| 121 | Eltrombopag Olamine (Promacta) | $142.8M | 10,876 |
| 122 | Alpha-1-Proteinase Inhibitor (Prolastin C) | $137.9M | 12,352 |
| 123 | Dasatinib (Sprycel) | $136.8M | 10,389 |
| 124 | Oxycodone Hcl/Acetaminophen (Oxycodone-Acetaminophen) | $136.4M | 3,487,099 |
| 125 | Buprenorphine Hcl/Naloxone Hcl (Buprenorphine-Naloxone) | $135.8M | 696,008 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology